What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
Tuesday, XBiotech Inc (NASDAQ:XBIT) announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.The study examined the Natrunix (anti-interleukin-1alpha) antibody in combina
Express News | XBiotech Shares Are Trading Higher After the Company Shared Results From the 1-BETTER Study for Advanced Pancreatic Cancer
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...
XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind Dur
XBiotech Results From Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
PDF Version Kaplan-Meier Product Limit Comparison Overall Survival (OS) defined as from time of randomization to death. Natrunix + ON+5FU+LV (n=3) vs Placebo + ON+5FU+LV arms (n=32) w
XBiotech | 10-Q: Quarterly report
XBiotech Inc.'s (NASDAQ:XBIT) Market Cap up US$57m Last Week, Benefiting Both Retail Investors Who Own 45% as Well as Insiders
Key Insights XBiotech's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 50% of the business is held by the top 7 sharehol
XBiotech Inc.'s (NASDAQ:XBIT) Top Owners Are Retail Investors With 44% Stake, While 44% Is Held by Insiders
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersMSP Recovery (NASDAQ:LIFW) shares rose 23.1% to $1.49 during Monday's pre-market session. The market value of their outstanding shares is at $21.4 million. 60 Degrees (NASDAQ:SXTP) stock moved
XBiotech to Begin Constructing New R&D Facility on Its 48-acre Campus
PDF Version XBiotech Architectural Rendition of XBiotech's Planned R&D Facility XBiotech Architectural Rendition of XBiotech's Planned R&D Facility AUSTIN, Texas,
ARCT, EHTH and CRTO Are Among After Hour Movers
Companies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In Growth
Press Release: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis (Phase II Multicenter Study is Proceeding Well with High Anticipation) AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- X
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
PDF Version (Phase II Multicenter Study is Proceeding Well with High Anticipation)AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D.
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAkanda (NASDAQ:AKAN) shares increased by 13.5% to $0.63 during Tuesday's after-market session. Trading volume for this security closed at 668.1K, accounting for 276.8% of its average full-day v
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to eva
XBiotech Gets FDA Approval for Phase 2 Study of Potential Treatment for Rheumatoid Arthritis
XBiotech (XBIT) said Monday that the Food and Drug Administration authorized the launch of the company's phase 2 clinical trial to test Natrunix as a potential treatment for rheumatoid arthritis, a lo
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today reports that the FDA's Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test
Xbiotech Shares Rise 24% on Dutch Auction to Buy Up to $80M of Its Stock
By Chris Wack Xbiotech shares were up 24% to $4.31 Wednesday after the company said it began a modified Dutch auction issuer tender offer to buy up to $80 million of its common shares at a price not
XBiotech, Impel Top Healthcare Gainers; Intercept, Agile Among Losers
XBiotech Adds 15% on $80M Buyback Offer